|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Falzone L, Salomone S and Libra M:
Evolution of cancer pharmacological treatments at the turn of the
third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shafrir AL, Rice MS, Gupta M, Terry KL,
Rosner BA, Tamimi RM, Hecht JL and Tworoger SS: The association
between reproductive and hormonal factors and ovarian cancer by
estrogen-α and progesterone receptor status. Gynecol Oncol.
143:628–635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D'Alonzo M, Bounous VE, Villa M and Biglia
N: Current evidence of the oncological benefit-risk profile of
hormone replacement therapy. Medicina (Kaunas). 55:5732019.
View Article : Google Scholar
|
|
7
|
Craig ER, Londoño AI, Norian LA and Arend
RC: Metabolic risk factors and mechanisms of disease in epithelial
ovarian cancer: A review. Gynecol Oncol. 143:674–683. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fenga C, Gangemi S, Di Salvatore V,
Falzone L and Libra M: Immunological effects of occupational
exposure to lead (Review). Mol Med Rep. 15:3355–3360. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Falzone L, Marconi A, Loreto C, Franco S,
Spandidos DA and Libra M: Occupational exposure to carcinogens:
Benzene, pesticides and fibers (Review). Mol Med Rep. 14:4467–4474.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amir S, Shah STA, Mamoulakis C, Docea AO,
Kalantzi OI, Zachariou A, Calina D, Carvalho F, Sofikitis N,
Makrigiannakis A and Tsatsakis A: Endocrine disruptors acting on
estrogen and androgen pathways cause reproductive disorders through
multiple mechanisms: A review. Int J Environ Res Public Health.
18:14642021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ianoşi S, Ianoşi G, Neagoe D, Ionescu O,
Zlatian O, Docea AO, Badiu C, Sifaki M, Tsoukalas D, Tsatsakis AM,
et al: Age-dependent endocrine disorders involved in the
pathogenesis of refractory acne in women. Mol Med Rep.
14:5501–5506. 2016. View Article : Google Scholar
|
|
12
|
Del Pup L, Mantovani A, Cavaliere C,
Facchini G, Luce A, Sperlongano P, Caraglia M and Berretta M:
Carcinogenetic mechanisms of endocrine disruptors in female cancers
(Review). Oncol Rep. 36:603–612. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rachoń D: Endocrine disrupting chemicals
(EDCs) and female cancer: Informing the patients. Rev Endocr Metab
Disord. 16:359–364. 2015. View Article : Google Scholar
|
|
14
|
Shulman LP and Dungan JS: Cancer genetics:
Risks and mechanisms of cancer in women with inherited
susceptibility to epithelial ovarian cancer. Cancer Treat Res.
156:69–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gomes R, Spinola PD, Brant AC, Matta BP,
Nascimento CM, de Aquino Paes SM, Bonvicino CR, Dos Santos AC and
Moreira MA: Prevalence of germline variants in consensus
moderate-to-high-risk predisposition genes to hereditary breast and
ovarian cancer in BRCA1/2-negative Brazilian patients. Breast
Cancer Res Treat. 185:851–861. 2021. View Article : Google Scholar
|
|
16
|
Hodgson A and Turashvili G: Pathology of
hereditary breast and ovarian cancer. Front Oncol. 10:5317902020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jara L, Morales S, de Mayo T,
Gonzalez-Hormazabal P, Carrasco V and Godoy R: Mutations in BRCA1,
BRCA2 and other breast and ovarian cancer susceptibility genes in
Central and South American populations. Biol Res. 50:352017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tedaldi G, Tebaldi M, Zampiga V, Danesi R,
Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A,
et al: Multiple-gene panel analysis in a case series of 255 women
with hereditary breast and ovarian cancer. Oncotarget.
8:47064–47075. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanley GE, McAlpine JN, Miller D, Huntsman
D, Schrader KA, Blake Gilks C and Mitchell G: A population-based
analysis of germline BRCA1 and BRCA2 testing among ovarian cancer
patients in an era of histotype-specific approaches to ovarian
cancer prevention. BMC Cancer. 18:2542018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Madariaga A, Lheureux S and Oza AM:
Tailoring ovarian cancer treatment: Implications of BRCA1/2
mutations. Cancers (Basel). 11:4162019. View Article : Google Scholar
|
|
21
|
Ashour M and Ezzat Shafik H: Frequency of
germline mutations in BRCA1 and BRCA2 in ovarian cancer patients
and their effect on treatment outcome. Cancer Manag Res.
11:6275–6284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsaousis GN, Papadopoulou E, Apessos A,
Agiannitopoulos K, Pepe G, Kampouri S, Diamantopoulos N, Floros T,
Iosifidou R, Katopodi O, et al: Analysis of hereditary cancer
syndromes by using a panel of genes: Novel and multiple pathogenic
mutations. BMC Cancer. 19:5352019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakonechny QB and Gilks CB: Ovarian cancer
in hereditary cancer susceptibility syndromes. Surg Pathol Clin.
9:189–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishioka Y, Kobayashi K, Sagae S, Sugimura
M, Ishioka S, Nagata M, Terasawa K, Tokino T and Kudo R: Mutational
analysis of STK11 gene in ovarian carcinomas. Jpn J Cancer Res.
90:629–632. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McLemore MR, Miaskowski C, Aouizerat BE,
Chen LM and Dodd MJ: Epidemiological and genetic factors associated
with ovarian cancer. Cancer Nurs. 32:281–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faber MT, Kjær SK, Dehlendorff C,
Chang-Claude J, Andersen KK, Høgdall E, Webb PM and Jordan SJ;
Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer
Study Group; et al Cigarette smoking and risk of ovarian cancer: A
pooled analysis of 21 case-control studies. Cancer Causes Control.
24:989–1004. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Modugno F, Ness RB and Cottreau CM:
Cigarette smoking and the risk of mucinous and nonmucinous
epithelial ovarian cancer. Epidemiology. 13:467–471. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Brien KM, Tworoger SS, Harris HR,
Anderson GL, Weinberg CR, Trabert B, Kaunitz AM, D'Aloisio AA,
Sandler DP and Wentzensen N: Association of powder use in the
genital area with risk of ovarian cancer. JAMA. 323:49–59. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fletcher NM, Harper AK, Memaj I, Fan R,
Morris RT and Saed GM: Molecular basis supporting the association
of talcum powder use with increased risk of ovarian cancer. Reprod
Sci. 26:1603–1612. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berge W, Mundt K, Luu H and Boffetta P:
Genital use of talc and risk of ovarian cancer: A meta-analysis.
Eur J Cancer Prev. 27:248–257. 2018. View Article : Google Scholar
|
|
31
|
Troisi R, Bjørge T, Gissler M, Grotmol T,
Kitahara CM, Myrtveit Saether SM, Ording AG, Sköld C, Sørensen HT,
Trabert B and Glimelius I: The role of pregnancy, perinatal factors
and hormones in maternal cancer risk: A review of the evidence. J
Intern Med. 283:430–445. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Havrilesky LJ, Moorman PG, Lowery WJ,
Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ,
Hasselblad V, Sanders GD and Myers ER: Oral contraceptive pills as
primary prevention for ovarian cancer: A systematic review and
meta-analysis. Obstet Gynecol. 122:139–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang Z, Gao Y, Wen W, Li H, Zheng W, Shu
XO and Beeghly-Fadiel A: Contraceptive methods and ovarian cancer
risk among Chinese women: A report from the shanghai women's health
study. Int J Cancer. 137:607–614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goff B: Symptoms associated with ovarian
cancer. Clin Obstet Gynecol. 55:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bankhead CR, Kehoe ST and Austoker J:
Symptoms associated with diagnosis of ovarian cancer: A systematic
review. BJOG. 112:857–865. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rossing MA, Wicklund KG, Cushing-Haugen KL
and Weiss NS: Predictive value of symptoms for early detection of
ovarian cancer. J Natl Cancer Inst. 102:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kehoe S: FIGO staging in ovarian carcinoma
and histological subtypes. J Gynecol Oncol. 31:e702020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tokunaga H, Shimada M, Ishikawa M and
Yaegashi N: TNM classification of gynaecological malignant tumours,
eighth edition: Changes between the seventh and eighth editions.
Jpn J Clin Oncol. 49:311–320. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chua KJC, Patel RD, Trivedi R, Greenberg
P, Beiter K, Magliaro T, Patel U and Varughese J: Accuracy in
referrals to gynecologic oncologists based on clinical presentation
for ovarian mass. Diagnostics (Basel). 10:1062020. View Article : Google Scholar
|
|
40
|
Barnes D, Rivera R, Gibson S, Craig C,
Cragun J, Monk B and Chase D: The utility of patient reported data
in a gynecologic oncology clinic. Gynecol Oncol Res Pract. 5:42018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Funston G, Van Melle M, Baun ML, Jensen H,
Helsper C, Emery J, Crosbie EJ, Thompson M, Hamilton W and Walter
FM: Variation in the initial assessment and investigation for
ovarian cancer in symptomatic women: A systematic review of
international guidelines. BMC Cancer. 19:10282019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu JH and Zanotti KM: Management of the
adnexal mass. Obstet Gynecol. 117:1413–1428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chan KK, Tam KF, Tse KY and Ngan HY: The
role of regular physical examination in the detection of ovarian
cancer recurrence. Gynecol Oncol. 110:158–161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Scholler N and Urban N: CA125 in ovarian
cancer. Biomark Med. 1:513–523. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dochez V, Caillon H, Vaucel E, Dimet J,
Winer N and Ducarme G: Biomarkers and algorithms for diagnosis of
ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res.
12:282019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Andersen MR, Goff BA, Lowe KA, Scholler N,
Bergan L, Drescher CW, Paley P and Urban N: Use of a symptom index,
CA125, and HE4 to predict ovarian cancer. Gynecol Oncol.
116:378–383. 2010. View Article : Google Scholar
|
|
47
|
Bastani A, Asghary A, Heidari MH and
Karimi-Busheri F: Evaluation of the sensitivity and specificity of
serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial
ovarian cancer patients. Eur J Gynaecol Oncol. 38:418–424.
2017.
|
|
48
|
Fischerova D and Burgetova A: Imaging
techniques for the evaluation of ovarian cancer. Best Pract Res
Clin Obstet Gynaecol. 28:697–720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
van Nagell JR Jr and Hoff JT: Transvaginal
ultrasonography in ovarian cancer screening: Current perspectives.
Int J Womens Health. 6:25–33. 2013. View Article : Google Scholar :
|
|
50
|
Zhang X, Meng X, Dou T and Sun H:
Diagnostic accuracy of transvaginal ultrasound examination for
assigning a specific diagnosis to adnexal masses: A meta-analysis.
Exp Ther Med. 20:2652020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Meng XF, Zhu SC, Sun SJ, Guo JC and Wang
X: Diffusion weighted imaging for the differential diagnosis of
benign vs. malignant ovarian neoplasms. Oncol Lett. 11:3795–3802.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qiao JJ, Yu J, Yu Z, Li N, Song C and Li
M: Contrast-enhanced ultrasonography in differential diagnosis of
benign and malignant ovarian tumors. PLoS One. 10:e01188722015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sahdev A: CT in ovarian cancer staging:
How to review and report with emphasis on abdominal and pelvic
disease for surgical planning. Cancer Imaging. 16:192016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Thabet A, Somarouthu B, Oliva E, Gervais
DA, Hahn PF and Lee SI: Image-guided ovarian mass biopsy: Efficacy
and safety. J Vasc Interv Radiol. 25:1922–1927.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Khiewvan B, Torigian DA, Emamzadehfard S,
Paydary K, Salavati A, Houshmand S, Werner TJ and Alavi A: An
update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J
Nucl Med Mol Imaging. 44:1079–1091. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao C, Li S, Zhao M, Zhu H and Zhu X:
Prognostic values of DNA mismatch repair genes in ovarian cancer
patients treated with platinum-based chemotherapy. Arch Gynecol
Obstet. 297:153–159. 2018. View Article : Google Scholar :
|
|
57
|
Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya
K, Oyama T, Mochizuki H and Omata M: Multigene panel analysis
identified germline mutations of DNA repair genes in breast and
ovarian cancer. Mol Genet Genomic Med. 3:459–466. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Missaoui N, Salhi S, Bdioui A, Mestiri S,
Abdessayed N, Mokni M and Yacoubi MT: Immunohistochemical
characterization improves the reproducibility of the histological
diagnosis of ovarian carcinoma. Asian Pac J Cancer Prev.
19:2545–2551. 2018.PubMed/NCBI
|
|
59
|
Zlatian OM, Comănescu MV, Roşu AF, Roşu L,
Cruce M, Găman AE, Călina CD and Sfredel V: Histochemical and
immunohistochemical evidence of tumor heterogeneity in colorectal
cancer. Rom J Morphol Embryol. 56:175–181. 2015.PubMed/NCBI
|
|
60
|
Docea AO, Mitruţ P, Grigore D, Pirici D,
Călina DC and Gofiţă E: Immunohistochemical expression of TGF beta
(TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal
variant of gastric adenocarcinomas. Rom J Morphol Embryol. 53(Suppl
3): S683–S692. 2012.
|
|
61
|
Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung
KW, Kim JW, Park SY and Won YJ: Changes in ovarian cancer survival
during the 20 years before the era of targeted therapy. BMC Cancer.
18:6012018. View Article : Google Scholar
|
|
62
|
Wu J, Sun H, Yang L, Deng Y, Yan Y, Wang
S, Yang G and Ma H: Improved survival in ovarian cancer, with
widening survival gaps of races and socioeconomic status: A period
analysis, 1983-2012. J Cancer. 9:3548–3556. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Timmermans M, Sonke GS, Van de Vijver KK,
van der Aa MA and Kruitwagen RF: No improvement in long-term
survival for epithelial ovarian cancer patients: A population-based
study between 1989 and 2014 in the Netherlands. Eur J Cancer.
88:31–37. 2018. View Article : Google Scholar
|
|
64
|
Nagle CM, Francis JE, Nelson AE, Zorbas H,
Luxford K, de Fazio A, Fereday S, Bowtell DD, Green AC and Webb PM:
Reducing time to diagnosis does not improve outcomes for women with
symptomatic ovarian cancer: A report from the Australian ovarian
cancer study group. J Clin Oncol. 29:2253–2258. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Engel J, Eckel R, Schubert-Fritschle G,
Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J and Hölzel D:
Moderate progress for ovarian cancer in the last 20 years:
Prolongation of survival, but no improvement in the cure rate. Eur
J Cancer. 38:2435–2445. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Martín-Cameán M, Delgado-Sánchez E, Piñera
A, Diestro MD, De Santiago J and Zapardiel I: The role of surgery
in advanced epithelial ovarian cancer. Ecancermedicalscience.
10:6662016.PubMed/NCBI
|
|
67
|
Vinotha T, Anitha T, Ajit S, Rachel C and
Abraham P: The role of completion surgery in ovarian cancer. J
Obstet Gynaecol India. 66(Suppl 1): S435–S440. 2016. View Article : Google Scholar
|
|
68
|
Fagotti A, Perelli F, Pedone L and Scambia
G: Current recommendations for minimally invasive surgical staging
in ovarian cancer. Curr Treat Options Oncol. 17:32016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hall M, Savvatis K, Nixon K, Kyrgiou M,
Hariharan K, Padwick M, Owens O, Cunnea P, Campbell J, Farthing A,
et al: Maximal-effort cytoreductive surgery for ovarian cancer
patients with a high tumor burden: Variations in practice and
impact on outcome. Ann Surg Oncol. 26:2943–2951. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shih KK and Chi DS: Maximal cytoreductive
effort in epithelial ovarian cancer surgery. J Gynecol Oncol.
21:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Suh DH, Chang SJ, Song T, Lee S, Kang WD,
Lee SJ, Roh JW, Joo WD, Yoon JH, Jeong DH, et al: Practice
guidelines for management of ovarian cancer in Korea: A Korean
society of gynecologic oncology consensus statement. J Gynecol
Oncol. 29:e562018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kim SR, Kotsopoulos J, Sun P, Bernardini
M, Laframboise S, Ferguson S, Rosen B, Narod SA and May T: The
impacts of neoadjuvant chemotherapy and of cytoreductive surgery on
ten-year survival from advanced ovarian cancer. Int J Gynaecol
Obstet. 2017.Epub ahead of print.
|
|
73
|
Choi N, Chang JH, Kim S and Kim HJ:
Radiation for persistent or recurrent epithelial ovarian cancer: A
need for reassessment. Radiat Oncol J. 35:144–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Dowdy SC, Metzinger DS, Gebhart JB,
Srivatsa P, Haddock MG, Suman VJ and Podratz KC: Salvage
whole-abdominal radiation therapy after second-look laparotomy or
secondary debulking surgery in patients with ovarian cancer.
Gynecol Oncol. 96:389–394. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Shimada T, Saito T, Shimokawa M, Shimamoto
K, Matsushita S, Yamaguchi S, Ariyoshi K and Okadome M: Improvement
in the prognosis of ovarian cancer in the era before addition of
molecular targeting therapy. Jpn J Clin Oncol. 47:494–498. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ledermann JA: First-line treatment of
ovarian cancer: Questions and controversies to address. Ther Adv
Med Oncol. 10:17588359187682322018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sato S and Itamochi H: Neoadjuvant
chemotherapy in advanced ovarian cancer: Latest results and place
in therapy. Ther Adv Med Oncol. 6:293–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chambers LM, Son J, Radeva M and
DeBernardo R: Evaluation of non-completion of intraperitoneal
chemotherapy in patients with advanced epithelial ovarian cancer. J
Gynecol Oncol. 30:e932019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yoon JY, Koo YJ, Kim MJ, Kim TJ, Lim KT
and Lee KH: Survival outcomes and toxicity of intraoperative
intraperitoneal chemotherapy in advanced epithelial ovarian cancer.
Obstet Gynecol Sci. 57:484–491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chan JK, Brady MF, Penson RT, Huang H,
Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson
SA, et al: Weekly vs. Every-3-week paclitaxel and carboplatin for
ovarian cancer. N Engl J Med. 374:738–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Pignata S, Scambia G, Katsaros D, Gallo C,
Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F,
Panici PB, et al: Carboplatin plus paclitaxel once a week versus
every 3 weeks in patients with advanced ovarian cancer (MITO-7): A
randomised, multicentre, open-label, phase 3 trial. Lancet Oncol.
15:396–405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Katsumata N, Yasuda M, Isonishi S,
Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S,
Terauchi F, et al: Long-term results of dose-dense paclitaxel and
carboplatin versus conventional paclitaxel and carboplatin for
treatment of advanced epithelial ovarian, fallopian tube, or
primary peritoneal cancer (JGOG 3016): A randomised, controlled,
open-label trial. Lancet Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Marchetti C, Muzii L, Romito A and
Benedetti Panici P: First-line treatment of women with advanced
ovarian cancer: Focus on bevacizumab. Onco Targets Ther.
12:1095–1103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Komiyama S, Kato K, Inokuchi Y, Takano H,
Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T,
et al: Bevacizumab combined with platinum-taxane chemotherapy as
first-line treatment for advanced ovarian cancer: A prospective
observational study of safety and efficacy in Japanese patients
(JGOG3022 trial). Int J Clin Oncol. 24:103–114. 2019. View Article : Google Scholar
|
|
85
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Qian X, Qin J, Pan S, Li X, Pan Y and Ma
S: Maintenance therapy in ovarian cancer with targeted agents
improves PFS and OS: A systematic review and meta-analysis. PLoS
One. 10:e01390262015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hess LM, Rong N, Monahan PO, Gupta P,
Thomaskutty C and Matei D: Continued chemotherapy after complete
response to primary therapy among women with advanced ovarian
cancer: A meta-analysis. Cancer. 116:5251–5260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Baert T, Ferrero A, Sehouli J, O'Donnell
DM, González-Martín A, Joly F, van der Velden J, Blecharz P, Tan
DSP, Querleu D, et al: The systemic treatment of recurrent ovarian
cancer revisited. Ann Oncol. Mar 3–2021.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lindemann K, Gao B, Mapagu C, Fereday S,
Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study
Group; Harnett PR, Bowtell DDL and DeFazio A: Response rates to
second-line platinum-based therapy in ovarian cancer patients
challenge the clinical definition of platinum resistance. Gynecol
Oncol. 150:239–246. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Guo B, Lian W, Liu S, Cao Y and Liu J:
Comparison of diagnostic values between CA125 combined with CA199
and ultrasound combined with CT in ovarian cancer. Oncol Lett.
17:5523–5528. 2019.PubMed/NCBI
|
|
92
|
Mancari R, Cutillo G, Bruno V, Vincenzoni
C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B and Vizza
E: Development of new medical treatment for epithelial ovarian
cancer recurrence. Gland Surg. 9:1149–1163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kozłowska E, Vallius T, Hynninen J,
Hietanen S, Färkkilä A and Hautaniemi S: Virtual clinical trials
identify effective combination therapies in ovarian cancer. Sci
Rep. 9:186782019. View Article : Google Scholar
|
|
94
|
Burger RA, Sill MW, Monk BJ, Greer BE and
Sorosky JI: Phase II trial of bevacizumab in persistent or
recurrent epithelial ovarian cancer or primary peritoneal cancer: A
gynecologic oncology group study. J Clin Oncol. 25:5165–5171. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Bamias A, Gibbs E, Khoon Lee C, Davies L,
Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza
MR, et al: Bevacizumab with or after chemotherapy for
platinum-resistant recurrent ovarian cancer: Exploratory analyses
of the AURELIA trial. Ann Oncol. 28:1842–1848. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Luvero D, Milani A and Ledermann JA:
Treatment options in recurrent ovarian cancer: Latest evidence and
clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Dockery LE, Tew WP, Ding K and Moore KN:
Tolerance and toxicity of the PARP inhibitor olaparib in older
women with epithelial ovarian cancer. Gynecol Oncol. 147:509–513.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kaufman B, Shapira-Frommer R, Schmutzler
RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G,
Stemmer SM, Hubert A, et al: Olaparib monotherapy in patients with
advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol.
33:244–250. 2015. View Article : Google Scholar
|
|
99
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI
|
|
100
|
Cortez AJ, Tudrej P, Kujawa KA and
Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother
Pharmacol. 81:17–38. 2018. View Article : Google Scholar :
|
|
101
|
Jiang X, Li W, Li X, Bai H and Zhang Z:
Current status and future prospects of PARP inhibitor clinical
trials in ovarian cancer. Cancer Manag Res. 11:4371–4390. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Banerjee S, Gonzalez-Martin A, Harter P,
Lorusso D, Moore KN, Oaknin A and Ray-Coquard I: First-line PARP
inhibitors in ovarian cancer: Summary of an ESMO Open-Cancer
Horizons round-table discussion. ESMO Open. 5:e0011102020.
View Article : Google Scholar
|
|
104
|
Ray-Coquard I, Pautier P, Pignata S, Pérol
D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N,
Mäenpää J, et al: Olaparib plus bevacizumab as first-line
maintenance in ovarian cancer. N Engl J Med. 381:2416–2428. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
González-Martín A, Pothuri B, Vergote I,
DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D,
Hoskins P, Freyer G, et al: Niraparib in patients with newly
diagnosed advanced ovarian cancer. N Engl J Med. 381:2391–2402.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Pujade-Lauraine E, Ledermann JA, Selle F,
Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A,
Pignata S, et al: Olaparib tablets as maintenance therapy in
patients with platinum-sensitive, relapsed ovarian cancer and a
BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised,
placebo-controlled, phase 3 trial. Lancet Oncol. 18:1274–1284.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al: Niraparib maintenance therapy in platinum-sensitive,
recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott CL, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
patients with platinum-sensitive relapsed serous ovarian cancer: A
preplanned retrospective analysis of outcomes by BRCA status in a
randomised phase 2 trial. Lancet Oncol. 15:852–861. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Balasubramaniam S, Beaver JA, Horton S,
Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J,
et al: FDA approval summary: Rucaparib for the treatment of
patients with deleterious BRCA mutation-associated advanced ovarian
cancer. Clin Cancer Res. 23:7165–7170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Leonardi GC, Candido S, Falzone L,
Spandidos DA and Libra M: Cutaneous melanoma and the immunotherapy
revolution (Review). Int J Oncol. 57:609–618. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Vivarelli S, Falzone L, Grillo CM,
Scandurra G, Torino F and Libra M: Cancer management during
COVID-19 pandemic: Is immune checkpoint inhibitors-based
immunotherapy harmful or beneficial? Cancers (Basel). 12:22372020.
View Article : Google Scholar
|
|
112
|
Christofi T, Baritaki S, Falzone L, Libra
M and Zaravinos A: Current perspectives in cancer immunotherapy.
Cancers (Basel). 11:14722019. View Article : Google Scholar
|
|
113
|
Liu JF, Gordon M, Veneris J, Braiteh F,
Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, et
al: Safety, clinical activity and biomarker assessments of
atezolizumab from a Phase I study in advanced/recurrent ovarian and
uterine cancers. Gynecol Oncol. 154:314–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Varga A, Piha-Paul S, Ott PA, Mehnert JM,
Berton-Rigaud D, Morosky A, Yang P, Ruman J and Matei D:
Pembrolizumab in patients with programmed death ligand 1-positive
advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol.
152:243–250. 2019. View Article : Google Scholar
|
|
115
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Hodi FS, Butler M, Oble DA, Seiden MV,
Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, et al:
Immunologic and clinical effects of antibody blockade of cytotoxic
T lymphocyte-associated antigen 4 in previously vaccinated cancer
patients. Proc Natl Acad Sci USA. 105:3005–3010. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zamarin D, Burger RA, Sill MW, Powell DJ
Jr, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews
C, et al: Randomized phase II trial of nivolumab versus nivolumab
and ipilimumab for recurrent or persistent ovarian cancer: An NRG
oncology study. J Clin Oncol. 38:1814–1823. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Palaia I, Tomao F, Sassu CM, Musacchio L
and Benedetti Panici P: Immunotherapy for ovarian cancer: Recent
advances and combination therapeutic approaches. Onco Targets Ther.
13:6109–6129. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Chandra A, Pius C, Nabeel M, Nair M,
Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status
and strategies for improving therapeutic outcomes. Cancer Med.
8:7018–7031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gotlieb WH, Amant F, Advani S, Goswami C,
Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF and Vergote I:
Intravenous aflibercept for treatment of recurrent symptomatic
malignant ascites in patients with advanced ovarian cancer: A phase
2, randomised, double-blind, placebo-controlled study. Lancet
Oncol. 13:154–162. 2012. View Article : Google Scholar
|
|
121
|
McGee J, Bookman M, Harter P, Marth C,
McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, et
al: Fifth ovarian cancer consensus conference: Individualized
therapy and patient factors. Ann Oncol. 28:702–710. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Aletti GD, Garbi A, Messori P, Achilarre
MT, Zanagnolo V, Rizzo S, Alessi S, Bocciolone L, Landoni F, Biffi
R, et al: Multidisciplinary approach in the management of advanced
ovarian cancer patients: A personalized approach. Results from a
specialized ovarian cancer unit. Gynecol Oncol. 144:468–473. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Pillay B, Wootten AC, Crowe H, Corcoran N,
Tran B, Bowden P, Crowe J and Costello AJ: The impact of
multidisciplinary team meetings on patient assessment, management
and outcomes in oncology settings: A systematic review of the
literature. Cancer Treat Rev. 42:56–72. 2016. View Article : Google Scholar
|
|
124
|
Junor EJ, Hole DJ and Gillis CR:
Management of ovarian cancer: Referral to a multidisciplinary team
matters. Br J Cancer. 70:363–370. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Gleeson M, Meiser B, Barlow-Stewart K,
Trainer AH, Tucker K, Watts KJ, Friedlander M and Kasparian N:
Communication and information needs of women diagnosed with ovarian
cancer regarding treatment-focused genetic testing. Oncol Nurs
Forum. 40:275–283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Stead ML, Brown JM, Fallowfield L and
Selby P: Lack of communication between healthcare professionals and
women with ovarian cancer about sexual issues. Br J Cancer.
88:666–671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Selby P, Gillis C and Haward R: Benefits
from specialised cancer care. Lancet. 348:313–318. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
August DA, Carpenter LC, Harness JK,
Delosh T, Cody RL, Adler DD, Oberman H, Wilkins E, Schottenfeld D
and McNeely SG: Benefits of a multidisciplinary approach to breast
care. J Surg Oncol. 53:161–167. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Vinciguerra V, Degnan TJ, Sciortino A,
O'Connell M, Moore T, Brody R, Budman D, Eng M and Carlton D: A
comparative assessment of home versus hospital comprehensive
treatment for advanced cancer patients. J Clin Oncol. 4:1521–1528.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Heudel PE, Devouassoux-Shisheboran M,
Taieb S, Genestie C, Selle F, Morice P, Rouzier R and Ray-Coquard
I: Multidisciplinary management of advanced ovarian cancer for an
optimal therapeutic strategy. Eur J Gynaecol Oncol. 38:175–180.
2017.PubMed/NCBI
|
|
131
|
Bjørn SF, Schnack TH, Lajer H, Christensen
IJ, Lundvall L, Thomsen LN and Høgdall C: Classification of ovarian
cancer surgery facilitates treatment decisions in a gynecological
multi-disciplinary team. Int J Gynecol Cancer. 27:382–389. 2017.
View Article : Google Scholar
|
|
132
|
Pozzar RA and Berry DL: Patient-centered
research priorities in ovarian cancer: A systematic review of
potential determinants of guideline care. Gynecol Oncol.
147:714–722. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Moterani VC, Tiezzi DG, de Andrade JM and
Candido Dos Reis FJ: Analysis of the relationship between hospital
characteristics and survival in ovarian cancer: A historical
cohort. J Surg Oncol. 122:1802–1807. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wright JD, Chen L, Hou JY, Burke WM,
Tergas AI, Ananth CV, Neugut AI and Hershman DL: Association of
hospital volume and quality of care with survival for ovarian
cancer. Obstet Gynecol. 130:545–553. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Vernooij F, Heintz AP, Coebergh JW,
Massuger LF, Witteveen PO and van der Graaf Y: Specialized and
high-volume care leads to better outcomes of ovarian cancer
treatment in the Netherlands. Gynecol Oncol. 112:455–461. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ke KM, Blazeby JM, Strong S, Carroll FE,
Ness AR and Hollingworth W: Are multidisciplinary teams in
secondary care cost-effective? A systematic review of the
literature. Cost Eff Resour Alloc. 11:72013. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Mercado C, Zingmond D, Karlan BY, Sekaris
E, Gross J, Maggard-Gibbons M, Tomlinson JS and Ko CY: Quality of
care in advanced ovarian cancer: The importance of provider
specialty. Gynecol Oncol. 117:18–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Long B, Chang J, Ziogas A, Tewari KS,
Anton-Culver H and Bristow RE: Impact of race, socioeconomic
status, and the health care system on the treatment of
advanced-stage ovarian cancer in California. Am J Obstet Gynecol.
212:468.e1–9. 2015. View Article : Google Scholar
|
|
139
|
Scott R, Hawarden A, Russell B and
Edmondson RJ: Decision-making in gynaecological oncology
multidisciplinary team meetings: A cross-sectional, observational
study of ovarian cancer cases. Oncol Res Treat. 43:70–77. 2020.
View Article : Google Scholar
|
|
140
|
Rausei S, Uccella S, D'Alessandro V,
Gisone B, Frattini F, Lianos G, Rovera F, Boni L, Dionigi G and
Ghezzi F: Aggressive surgery for advanced ovarian cancer performed
by a multidisciplinary team: A retrospective analysis on a large
series of patients. Surg Open Sci. 1:43–47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Burton E, Chase D, Yamamoto M, de Guzman
J, Imagawa D and Berman ML: Surgical management of recurrent
ovarian cancer: The advantage of collaborative surgical management
and a multidisciplinary approach. Gynecol Oncol. 120:29–32. 2011.
View Article : Google Scholar
|
|
142
|
Forstner R, Meissnitzer M and Cunha TM:
Update on imaging of ovarian cancer. Curr Radiol Rep. 4:312016.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Guerriero S, Saba L, Alcazar JL, Pascual
MA, Ajossa S, Perniciano M, Piras A, Sedda F, Peddes C, Fabbri P,
et al: Past, present and future ultrasonographic techniques for
analyzing ovarian masses. Womens Health (Lond). 11:369–383. 2015.
View Article : Google Scholar
|
|
144
|
Avril S: Histopathological markers of
treatment response and recurrence risk in ovarian cancers and
borderline tumors. Pathologe. 38(Suppl 3): S180–S191. 2017.
View Article : Google Scholar
|
|
145
|
Rojas V, Hirshfield KM, Ganesan S and
Rodriguez-Rodriguez L: Molecular characterization of epithelial
ovarian cancer: Implications for diagnosis and treatment. Int J Mol
Sci. 17:21132016. View Article : Google Scholar
|
|
146
|
Ramalingam P: Morphologic,
immunophenotypic, and molecular features of epithelial ovarian
cancer. Oncology (Williston Park). 30:166–176. 2016.
|
|
147
|
Lalwani N, Prasad SR, Vikram R, Shanbhogue
AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic
features of ovarian cancers: Implications for diagnosis and
treatment. Radiographics. 31:625–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kim H, Choi DH, Park W, Im YH, Ahn JS,
Park YH, Nam SJ, Kim SW, Lee JE, Yu JH, et al: The association
between non-breast and ovary cancers and BRCA mutation in first-
and second-degree relatives of high-risk breast cancer patients: A
large-scale study of Koreans. Hered Cancer Clin Pract. 17:12019.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Pruthi S, Gostout BS and Lindor NM:
Identification and management of women with BRCA mutations or
hereditary predisposition for breast and ovarian cancer. Mayo Clin
Proc. 85:1111–1120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Di Furia L, Rusciano MR, Nardini L, Rossi
P, Giammarchi C, Vittori E, Tilocca S, Russo FL, Montuori P,
Triassi M, et al: A nutritional approach to the prevention of
cancer: From assessment to personalized intervention. Transl Med
UniSa. 13:33–41. 2016.PubMed/NCBI
|
|
151
|
Zheng B, Shen H, Han H, Han T and Qin Y:
Dietary fiber intake and reduced risk of ovarian cancer: A
meta-analysis. Nutr J. 17:992018. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Crane TE, Khulpateea BR, Alberts DS,
Basen-Engquist K and Thomson CA: Dietary intake and ovarian cancer
risk: A systematic review. Cancer Epidemiol Biomarkers Prev.
23:255–273. 2014. View Article : Google Scholar :
|
|
153
|
Montagnese C, Porciello G, Vitale S,
Palumbo E, Crispo A, Grimaldi M, Calabrese I, Pica R, Prete M,
Falzone L, et al: Quality of life in women diagnosed with breast
cancer after a 12-month treatment of lifestyle modifications.
Nutrients. 13:1362020. View Article : Google Scholar
|
|
154
|
Porciello G, Montagnese C, Crispo A,
Grimaldi M, Libra M, Vitale S, Palumbo E, Pica R, Calabrese I,
Cubisino S, et al: Mediterranean diet and quality of life in women
treated for breast cancer: A baseline analysis of DEDiCa
multicentre trial. PLoS One. 15:e02398032020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Hansen JM, Nagle CM, Ibiebele TI, Grant
PT, Obermair A, Friedlander ML, DeFazio A and Webb PM; Ovarian
Cancer Prognosis Lifestyle Study Group: A healthy lifestyle and
survival among women with ovarian cancer. Int J Cancer.
147:3361–3369. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Thomson CA, E Crane T, Wertheim BC,
Neuhouser ML, Li W, Snetselaar LG, Basen-Engquist KM, Zhou Y and
Irwin ML: Diet quality and survival after ovarian cancer: Results
from the women's health initiative. J Natl Cancer Inst. 106. pp.
dju3142014, View Article : Google Scholar
|
|
157
|
Peres LC, Cushing-Haugen KL, Anglesio M,
Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks
CB, Harris HR, et al: Histotype classification of ovarian
carcinoma: A comparison of approaches. Gynecol Oncol. 151:53–60.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Jacome LS, Deshmukh SK, Thulasiraman P,
Holliday NP and Singh S: Impact of COVID-19 pandemic on ovarian
cancer management: Adjusting to the new normal. Cancer anag Res.
13:359–366. 2021.
|
|
159
|
Vivarelli S, Falzone L, Torino F,
Scandurra G, Russo G, Bordonaro R, Pappalardo F, Spandidos DA,
Raciti G and Libra M: Immune-checkpoint inhibitors from cancer to
COVID-19: A promising avenue for the treatment of patients with
COVID-19 (Review). Int J Oncol. 58:145–157. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Tsatsakis A, Calina D, Falzone L, Petrakis
D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et
al: SARS-CoV-2 pathophysiology and its clinical implications: An
integrative overview of the pharmacotherapeutic management of
COVID-19. Food Chem Toxicol. 146:1117692020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Zimmerman BS, Seidman D, Berger N,
Cascetta KP, Nezolosky M, Trlica K, Ryncarz A, Keeton C, Moshier E
and Tiersten A: Patient perception of telehealth services for
breast and gynecologic oncology care during the COVID-19 pandemic:
A single center survey-based study. J Breast Cancer. 23:542–552.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Mancebo G, Solé-Sedeño JM, Membrive I,
Taus A, Castells M, Serrano L, Carreras R and Miralpeix E:
Gynecologic cancer surveillance in the era of SARS-CoV-2
(COVID-19). Int J Gynecol Cancer. 5:ijgc-2020–001942. 2020.
|
|
163
|
Frey MK, Ellis AE, Zeligs K, Chapman-Davis
E, Thomas C, Christos PJ, Kolev V, Prasad-Hayes M, Cohen S, Holcomb
K and Blank SV: Impact of the coronavirus disease 2019 pandemic on
the quality of life for women with ovarian cancer. Am J Obstet
Gynecol. 223:725.e1–725.e9. 2020. View Article : Google Scholar
|
